Literature DB >> 34905060

Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.

Jintao Gu1, Nan Mu2, Bo Jia3, Qingdong Guo3, Luxiang Pan1, Maorong Zhu1, Wangqian Zhang1, Kuo Zhang1, Weina Li1, Meng Li1, Lichun Wei4, Xiaochang Xue5, Yingqi Zhang1, Wei Zhang1.   

Abstract

BACKGROUND: Compelling evidence suggests that glioblastoma (GBM) recurrence results from the expansion of a subset of tumor cells with robust intrinsic or therapy-induced radioresistance. However, the mechanisms underlying GBM radioresistance and recurrence remain elusive. To overcome obstacles in radioresistance research, we present a novel preclinical model ideally suited for radiobiological studies.
METHODS: With this model, we performed a screen and identified a radiation-tolerant persister (RTP) subpopulation. RNA sequencing was performed on RTP and parental cells to obtain mRNA and miRNA expression profiles. The regulatory mechanisms among NF-κB, YY1, miR-103a, XRCC3, and FGF2 were investigated by transcription factor activation profiling array analysis, chromatin immunoprecipitation, western blot analysis, luciferase reporter assays, and the MirTrap system. Transferrin-functionalized nanoparticles (Tf-NPs) were employed to improve blood-brain barrier permeability and RTP targeting.
RESULTS: RTP cells drive radioresistance by preferentially activating DNA damage repair and promoting stemness. Mechanistic investigations showed that continual radiation activates the NF-κB signaling cascade and promotes nuclear translocation of p65, leading to enhanced expression of YY1, the transcription factor that directly suppresses miR-103a transcription. Restoring miR-103a expression under these conditions suppressed the FGF2-XRCC3 axis and decreased the radioresistance capability. Moreover, Tf-NPs improved radiosensitivity and provided a significant survival benefit.
CONCLUSIONS: We suggest that the NF-κB-YY1-miR-103a regulatory axis is indispensable for the function of RTP cells in driving radioresistance and recurrence. Thus, our results identified a novel strategy for improving survival in patients with recurrent/refractory GBM. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2021.

Entities:  

Keywords:  DNA damage repair; glioblastoma; glioma stem cell; radioresistance

Mesh:

Substances:

Year:  2022        PMID: 34905060      PMCID: PMC9248405          DOI: 10.1093/neuonc/noab288

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  31 in total

Review 1.  Ionizing radiations induce apoptosis in TRAIL resistant cancer cells: in vivo and in vitro analysis.

Authors:  Marcela Fernandes Silva; Abdur Rehman Khokhar; Muhammad Zahid Qureshi; Ammad Ahmad Farooqi
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.

Authors:  Sergey Karakashev; Takeshi Fukumoto; Bo Zhao; Jianhuang Lin; Shuai Wu; Nail Fatkhutdinov; Pyoung-Hwa Park; Galina Semenova; Stephanie Jean; Mark G Cadungog; Mark E Borowsky; Andrew V Kossenkov; Qin Liu; Rugang Zhang
Journal:  Cancer Cell       Date:  2020-01-30       Impact factor: 31.743

Review 3.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

Authors:  Jason M Lajoie; Eric V Shusta
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

Review 4.  Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.

Authors:  Erik P Sulman; Nofisat Ismaila; Terri S Armstrong; Christina Tsien; Tracy T Batchelor; Tim Cloughesy; Evanthia Galanis; Mark Gilbert; Vinai Gondi; Mary Lovely; Minesh Mehta; Matthew P Mumber; Andrew Sloan; Susan M Chang
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

5.  Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.

Authors:  Surya Nagaraja; Nicholas A Vitanza; Pamelyn J Woo; Kathryn R Taylor; Fang Liu; Lei Zhang; Meng Li; Wei Meng; Anitha Ponnuswami; Wenchao Sun; Jie Ma; Esther Hulleman; Tomek Swigut; Joanna Wysocka; Yujie Tang; Michelle Monje
Journal:  Cancer Cell       Date:  2017-04-20       Impact factor: 31.743

6.  Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.

Authors:  Smile Echizenya; Yukiko Ishii; Satoshi Kitazawa; Tadashi Tanaka; Shun Matsuda; Eriko Watanabe; Masao Umekawa; Shunsuke Terasaka; Kiyohiro Houkin; Tomohisa Hatta; Tohru Natsume; Yoshimasa Maeda; Shin-Ichi Watanabe; Shinji Hagiwara; Toru Kondo
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

7.  MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.

Authors:  Jing Hu; Tao Sun; Hui Wang; Zhengxin Chen; Shuai Wang; Lifeng Yuan; Tingyu Liu; Hai-Ri Li; Pingping Wang; Yukuan Feng; Qinhong Wang; Roger E McLendon; Allan H Friedman; Stephen T Keir; Darell D Bigner; Jeff Rathmell; Xiang-Dong Fu; Qi-Jing Li; Huibo Wang; Xiao-Fan Wang
Journal:  Cancer Cell       Date:  2016-01-11       Impact factor: 31.743

Review 8.  FGF2: a novel druggable target for glioblastoma?

Authors:  Ana Jimenez-Pascual; Kelly Mitchell; Florian A Siebzehnrubl; Justin D Lathia
Journal:  Expert Opin Ther Targets       Date:  2020-03-16       Impact factor: 6.797

9.  Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.

Authors:  Tejpal Gupta; Sadhana Kannan; Sarbani Ghosh-Laskar; Jai Prakash Agarwal
Journal:  PLoS One       Date:  2018-07-06       Impact factor: 3.240

Review 10.  MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment.

Authors:  Lei Bian; Yiling Meng; Meichao Zhang; Dong Li
Journal:  Mol Cancer       Date:  2019-11-26       Impact factor: 27.401

View more
  5 in total

1.  Targeting adaptive radioresistance in glioblastoma.

Authors:  Satoru Osuka
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

2.  Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors.

Authors:  Yohan Walter; Anne Hubbard; Allie Benoit; Erika Jank; Olivia Salas; Destiny Jordan; Andrew Ekpenyong
Journal:  Biomedicines       Date:  2022-07-26

Review 3.  Multimodal targeting of glioma with functionalized nanoparticles.

Authors:  Hany E Marei
Journal:  Cancer Cell Int       Date:  2022-08-23       Impact factor: 6.429

4.  Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma.

Authors:  Xiao Liu; Zhengcong Cao; Nannan Liu; Guangxun Gao; Mingrui Du; Yingwen Wang; Boyang Cheng; Maorong Zhu; Bo Jia; Luxiang Pan; Wangqian Zhang; Yuran Jiang; Wei He; Linlin Xu; Wei Zhang; Qunxing An; Qingdong Guo; Jintao Gu
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

Review 5.  Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities.

Authors:  Amanda L Johnson; John Laterra; Hernando Lopez-Bertoni
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.